Exosome applications for the diagnosis and treatment of pancreatic ductal adenocarcinoma: An update (Review)

Oncol Rep. 2025 Jan;53(1):13. doi: 10.3892/or.2024.8846. Epub 2024 Nov 22.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a malignant neoplasm that typically manifests with subtle clinical manifestations in its early stages and frequently eludes diagnosis until the advanced phases of the disease. The limited therapeutic options available for PDAC significantly contribute to its high mortality rate, highlighting the urgent need for novel biomarkers capable of effectively identifying early clinical manifestations and facilitating precise diagnosis. The pivotal role of cellular exosomes in both the pathogenesis and therapeutic interventions for PDAC has been underscored. Furthermore, researchers have acknowledged the potential of exosomes as targeted drug carriers against regulatory cells in treating PDAC. The present article aims to provide a comprehensive review encompassing recent advancements in utilizing exosomes for elucidating mechanisms underlying disease development, patterns of metastasis, diagnostic techniques and treatment strategies associated with PDAC.

Keywords: PDAC; biomarker; diagnosis; exosome; treatment.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor* / metabolism
  • Carcinoma, Pancreatic Ductal* / diagnosis
  • Carcinoma, Pancreatic Ductal* / pathology
  • Carcinoma, Pancreatic Ductal* / therapy
  • Exosomes* / metabolism
  • Humans
  • Pancreatic Neoplasms* / diagnosis
  • Pancreatic Neoplasms* / pathology
  • Pancreatic Neoplasms* / therapy

Substances

  • Biomarkers, Tumor